RaQualia Pharma Inc.
Stock Price Chart
2026/07/30 UpdatedPrice Trend
2026/07/30 UpdatedPrice & Trading Details
2026/07/30 UpdatedPRICE
TRADING
Financial Performance
2026/07/26 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥2,918M | ¥1,901M | ¥3,108M | ¥3,980M |
| Gross Profit | ¥2,686M | ¥1,656M | ¥2,482M | ¥3,268M |
| Operating Income | ¥866M | -¥337M | -¥213M | ¥484M |
| Pretax Income | ¥857M | -¥287M | -¥315M | ¥497M |
| Net Income | ¥723M | -¥324M | -¥495M | ¥273M |
| EPS | ¥34.47 | -¥14.98 | -¥22.87 | - |
| Operating Margin | 29.69% | -17.74% | -6.87% | 12.15% |
| Balance Sheet | ||||
| Total Assets | ¥6,258M | ¥6,872M | ¥9,655M | ¥10,514M |
| Total Equity | ¥5,497M | ¥6,120M | ¥5,571M | ¥6,896M |
| Total Liabilities | ¥761M | ¥752M | ¥4,085M | ¥3,618M |
| Cash | ¥3,675M | ¥3,715M | ¥3,340M | ¥3,241M |
| Interest-bearing Debt | ¥222M | ¥368M | ¥3,452M | ¥2,902M |
| Equity Ratio | 87.84% | 89.06% | 57.69% | 65.59% |
| D/E Ratio | 0.04 | 0.06 | 0.62 | 0.42 |
| Cash Flow | ||||
| Operating CF | ¥1,480M | -¥719M | ¥181M | -¥354M |
| Investing CF | -¥48M | -¥135M | -¥3,666M | ¥124M |
| Financing CF | -¥30M | ¥793M | ¥2,982M | ¥378M |
| Free CF | ¥1,448M | -¥941M | ¥65M | -¥429M |
| Efficiency | ||||
| ROE | 13.16% | -5.29% | -8.89% | 3.96% |
| ROA | 11.56% | -4.71% | -5.13% | 2.60% |
Latest IR Information
-
【Lauoria Pharmaceuticals】Strengthening of Intellectual Property Rights through US Patent Grant for IRAK-M Protein Degradation Inducer | July 2026
Lauoria Pharmaceuticals' consolidated subsidiary, FIMEKSU, has received a patent grant in the United States for an IRAK-M protein degradation inducer. By strengthening research and development and intellectual property, the company aims to enhance long-term corporate value.
Read more -
【Rakuoilia Pharmaceutical】Addition of New Indications for tegoprazan in South Korea｜July 2026
Rakuoilia Pharmaceutical announced the addition of new indications for the gastric acid suppressant tegoprazan in South Korea through licensed partner HK Innoen. As of April 2026, South Korean sales reached approximately 110 billion yen, maintaining the market share at No.1.
Read more -
Notice of Conclusion of Therapeutic Development Agreement with Lazarus Pharmaceuticals, LLC Group through New Business Creation Model
Read more
Latest News (5 items)
Company Information
About
RaQualia Pharma Inc. engages in the research and development of pharmaceutical compounds worldwide. The company human products portfolio includes tegoprazan for gastroesophageal reflux disease; and grapiprant for cancer and pain management; RQ-00000008 for the treatment of osteoarthritis autoimmune disorders; RQ-00000010 to treat gastroparesis. It also provides veterinary products, such as capromorelin to treat anorexia in dogs and weight management in cats; grapiprant for osteoarthritis in dogs; RQ-00000008 to treat osteoarthritis and others; RQ-00317076 for pain; and RQ-00000010 for gut motility disorders, gastroparesis, functional dyspepsia, and chronic constipation. In addition, it provides RQ-00433412 for constipation, and cancer-related anorexia/cachexia syndrome; RQ-00000009 to treat alzheimer's; RQ-00466479, RQ-00350215, and RQ-00434739 to treat chronic pain; RQ-00310941 to treat D-IBS, IBD-remission stage symptoms; RQ-00201894 for gastroparesis, functional dyspepsia, and post-operative ileus; tamibarotene to treat higher-risk myelodysplastic syndrome and acute myeloid leukemia; and FIM-001 for cancer. The company was incorporated in 2008 and is headquartered in Nagoya, Japan.
